Position paperThe value of the polypill in cardiovascular disease: an Italian multidisciplinary Delphi panel consensusPerrone-Filardi, Pasqualea,b; Minghetti, Paolac; Menditto, Enricad; Bianchi, Stefanoe; Scaglione, Francescof,g; Trifirò, Gianlucah; Piccinocchi, Gaetanoi; Corona, Tiberioj; Gambarelli, Giorgiak; Izzi, Chiaral; Misciagna, Vincenzom; Putignano, Darian; Lopatriello, Stefanian; Cafiero, Daviden Author Information aDepartment of Advanced Biomedical Sciences, Federico II University of Naples bMediterranea Cardiocentro, Napoli cDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, Milano dDepartment of Pharmacy, CIRFF, Centre of Pharmacoeconomics, University of Naples Federico II, Napoli eU.O. Assistenza Farmaceutica Ospedaliera, Territoriale e Ricerca clinica, Ferrara fDepartment of Oncology and Hemato-oncology, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan gClinical Pharmacology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano hDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina iSocietà Italiana di Medicina Generale (SIMG), Napoli jU.O.C. Farmaceutica Territoriale, Pisa kA.O.U.Policlinico Umberto Primo lArea del Farmaco ASL RM A, Roma mA.O.U.C. Policlinico di Bari, Bari nHelaglobe SRL, Firenze, Italy Correspondence to Daria Putignano, Helaglobe SRL, Via Leonardo Da Vinci, 16, 50132 Firenze, Italy Tel: +39 0550050130; e-mail: [email protected] Received 15 July, 2020 Revised 17 September, 2020 Accepted 21 December, 2020 Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.jcardiovascularmedicine.com). Journal of Cardiovascular Medicine: April 2021 - Volume 22 - Issue 4 - p 246-258 doi: 10.2459/JCM.0000000000001159 Buy SDC Metrics Abstract The purpose of this work was to reach the consensus of a multidisciplinary and multistakeholder Italian panel on the value of polypill in cardiovascular disease, with respect to the clinical, technological, economic and organizational dimension. A three-step modified Delphi method was used to establish consensus. Eleven experts in the area of cardiology, pharmaceutical technology, general practice, hospital pharmacy, pharmacology, and health economics participated in the expert panel. To identify existing evidence concerning the value of polypill in the prevention of patients with cardiovascular disease, a systematic literature review was carried out according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement guidelines. In the first round, 22 statements were distributed to the panel. Panel members were asked to mark ‘agree’ or ‘disagree’ for each statement and provide any comments. The same voting method was again used for the second round. In the first round nine statements met consensus. In the second round, 10 statements reached consensus. Overall, consensus was reached for 19 statements representing five value polypill domains: clinical, technological, economic and organizational. During a final web meeting with all panel members consensus document open points were discussed. Panel members agreed to recognize polypill as effective in reducing cardiovascular events, blood pressure and lipids, cardiovascular risk and the weight of therapy, in therapeutic adherence improvement, in the absence of differences in bioavailability between drugs administered in fixed or free combinations and the better cost-effectiveness profile compared with standard care. This document represents a knowledge framework to inform decision makers of the value of polypill in cardiovascular prevention. © 2021 Italian Federation of Cardiology - I.F.C. All rights reserved.